Gilead To Withdraw U.S. Accelerated Approval For Trodelvy In Metastatic Urothelial Cancer After Consultation With FDA; Decision Follows TROPiCS-04 Study Not Meeting Overall Survival Endpoint; Other Trodelvy Indications Remain Unaffected

Benzinga · 10/18 12:37